Company Overview - Bandwidth (BAND) shares have increased by approximately 2.7% over the past month, underperforming the S&P 500 index [1] - The most recent earnings report is crucial for understanding the catalysts affecting the stock [1] Earnings Estimates - Estimates for Bandwidth have remained flat over the past month, with a significant shift of 300% in the consensus estimate [2] VGM Scores - Bandwidth has a strong Growth Score of A, but a low Momentum Score of F, and a Value Score of B, placing it in the second quintile for investment strategy [3] - The aggregate VGM Score for Bandwidth is A, indicating a strong overall performance across different investment strategies [3] Market Outlook - Bandwidth holds a Zacks Rank of 3 (Hold), suggesting an expectation of in-line returns in the upcoming months [4] Industry Performance - Bandwidth is part of the Zacks Communication - Infrastructure industry, where another player, CommScope (COMM), has seen a 19.5% increase in shares over the past month [5] - CommScope reported revenues of $1.11 billion for the last quarter, reflecting a year-over-year decline of 4.8%, with an EPS of $0.14 compared to -$0.08 a year ago [5] - CommScope is projected to have earnings of $0.24 per share for the current quarter, indicating a year-over-year decrease of 29.4% [6] - The Zacks Consensus Estimate for CommScope has remained unchanged over the last 30 days, and it also holds a Zacks Rank of 3 (Hold) [6]

Company Overview - CRISPR Therapeutics AG (CRSP) shares have increased by approximately 11.1% over the past month, outperforming the S&P 500 [1] - The most recent earnings report is essential for understanding the key drivers behind this performance [1] Earnings Estimates - Estimates for CRISPR Therapeutics have trended downward over the past month, with a consensus estimate shift of -20.48% [2] - The stock currently holds a Zacks Rank 3 (Hold), indicating an expectation of in-line returns in the coming months [4] VGM Scores - CRISPR Therapeutics has an average Growth Score of C and a Momentum Score of B, but a low Value Score of F, placing it in the bottom 20% for this investment strategy [3] - The overall aggregate VGM Score for the stock is D, which is relevant for investors not focused on a single strategy [3] Industry Performance - CRISPR Therapeutics is part of the Zacks Medical - Biomedical and Genetics industry, where Exact Sciences (EXAS) has gained 3.6% over the past month [5] - Exact Sciences reported revenues of $706.78 million for the last quarter, reflecting a year-over-year increase of +10.9% [5] - The expected loss for Exact Sciences in the current quarter is $0.08 per share, with a year-over-year change of +11.1% [6]

Core Viewpoint - Krystal Biotech, Inc. has experienced a decline of approximately 3.5% in share price over the past month, underperforming the S&P 500, raising questions about its upcoming earnings release and potential breakout [1] Estimates Movement - Estimates for Krystal Biotech have trended downward over the past month, with a consensus estimate shift of -12.86% [2] VGM Scores - Krystal Biotech holds a Growth Score of A, but has a low Momentum Score of F. The stock has a value grade of C, placing it in the middle 20% for this investment strategy, resulting in an aggregate VGM Score of C [3] Outlook - The overall trend of downward estimate revisions suggests a negative outlook for Krystal Biotech, which currently holds a Zacks Rank of 3 (Hold), indicating an expectation of in-line returns in the coming months [4] Industry Performance - Krystal Biotech is part of the Zacks Medical - Biomedical and Genetics industry. In contrast, Biogen Inc., another player in the same industry, has seen a gain of 12.5% over the past month [5] Biogen's Financials - Biogen reported revenues of $2.43 billion for the last quarter, reflecting a year-over-year increase of +6.1%. The EPS for the same period was $3.02, down from $3.67 a year ago [5] Biogen's Future Estimates - For the current quarter, Biogen is expected to report earnings of $4.11 per share, indicating a decline of -22.2% from the previous year. The Zacks Consensus Estimate for Biogen has changed by -0.6% over the last 30 days, and it also holds a Zacks Rank of 3 (Hold) [6]

Core Viewpoint - eBay shares have increased by approximately 7.5% since the last earnings report, outperforming the S&P 500, raising questions about the sustainability of this positive trend leading up to the next earnings release [1] Group 1: Earnings Report Insights - Recent earnings report indicates that estimates for eBay have trended upward over the past month, suggesting positive momentum [2] - The stock has a strong Growth Score of A, but a lower Momentum Score of C, and a Value Score of C, placing it in the middle 20% for the value investment strategy [3] Group 2: Future Outlook - The upward trend in estimates is promising, and eBay holds a Zacks Rank of 3 (Hold), indicating expectations for an in-line return in the coming months [4]

Company Overview - Tandem Diabetes Care, Inc. (TNDM) has seen its shares increase by approximately 6.5% over the past month, outperforming the S&P 500 [1] - The most recent earnings report is crucial for understanding the key drivers affecting the stock [1] Earnings Estimates - Estimates for Tandem Diabetes Care have trended downward over the past month, with the consensus estimate shifting by -19.45% [2] - The stock currently holds a Zacks Rank of 3 (Hold), indicating expectations for an in-line return in the coming months [4] VGM Scores - Tandem Diabetes Care has an average Growth Score of C, a Momentum Score of F, and a Value Score of C, placing it in the middle 20% for the value investment strategy [3] - The overall aggregate VGM Score for the stock is D, which is significant for investors not focused on a single strategy [3] Industry Performance - Tandem Diabetes Care is part of the Zacks Medical - Instruments industry, where another player, Intuitive Surgical, Inc. (ISRG), has gained 7.5% in the past month [5] - Intuitive Surgical reported revenues of $2.25 billion for the last quarter, reflecting a year-over-year increase of +19.2% [5] - The expected earnings for Intuitive Surgical in the current quarter are $1.92 per share, indicating a +7.9% change from the previous year [6]

Core Viewpoint - Red Robin (RRGB) reported quarterly earnings of $0.19 per share, significantly beating the Zacks Consensus Estimate of a loss of $0.57 per share, and showing improvement from a loss of $0.80 per share a year ago [1] Financial Performance - The company posted revenues of $392.35 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 1.28% and showing an increase from $388.54 million year-over-year [2] - Over the last four quarters, Red Robin has exceeded consensus revenue estimates four times, but has only surpassed consensus EPS estimates once [2] Stock Performance - Red Robin shares have declined approximately 39.2% since the beginning of the year, contrasting with the S&P 500's slight gain of 0.1% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.29 on revenues of $291.24 million, and for the current fiscal year, it is -$1.88 on revenues of $1.23 billion [7] - The estimate revisions trend for Red Robin is mixed, and future changes in estimates will be closely monitored following the recent earnings report [6][7] Industry Context - The Retail - Restaurants industry, to which Red Robin belongs, is currently ranked in the bottom 31% of over 250 Zacks industries, suggesting potential challenges ahead [8] - Comparatively, Darden Restaurants (DRI), another player in the same industry, is expected to report quarterly earnings of $2.92 per share, reflecting a year-over-year increase of 10.2% [9]

Core Viewpoint - Universal Health Services (UHS) shares have increased by approximately 12% over the past month, outperforming the S&P 500, raising questions about the sustainability of this trend leading up to the next earnings release [1] Estimates Movement - Estimates for Universal Health Services have trended upward over the past month, indicating positive sentiment among analysts [2] VGM Scores - Universal Health Services currently holds a strong Growth Score of A, a Momentum Score of B, and a Value Score of A, placing it in the top 20% for the value investment strategy, resulting in an aggregate VGM Score of A [3] Outlook - The upward trend in estimates suggests a promising outlook for Universal Health Services, which currently has a Zacks Rank of 3 (Hold), indicating expectations for an in-line return in the coming months [4] Industry Performance - Universal Health Services is part of the Zacks Medical - Hospital industry, where HCA Healthcare has gained 11.2% over the past month, reporting revenues of $18.32 billion for the last quarter, reflecting a year-over-year increase of 5.7% [5] - HCA is projected to report earnings of $6.20 per share for the current quarter, representing a year-over-year change of 12.7%, with the Zacks Consensus Estimate remaining unchanged over the last 30 days, also holding a Zacks Rank of 3 (Hold) and a VGM Score of A [6]

Core Viewpoint - CVS Health's shares have recently declined by 10.9% over the past week, but the formation of a hammer chart pattern suggests potential support and a possible trend reversal in the future [1][2]. Technical Analysis - The hammer chart pattern indicates a potential bottoming out, with reduced selling pressure, which could lead to a bullish trend [2][5]. - A hammer pattern typically forms during a downtrend, where the stock opens lower, makes a new low, but then closes near its opening price, indicating buying interest [4][5]. - The effectiveness of the hammer pattern is contingent on its placement on the chart and should be used alongside other bullish indicators [6]. Fundamental Analysis - There has been a recent upward trend in earnings estimate revisions for CVS, which is a positive sign for potential price appreciation [7]. - The consensus EPS estimate for CVS has increased by 4% over the last 30 days, reflecting analysts' optimism about the company's earnings potential [8]. - CVS holds a Zacks Rank of 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks, indicating strong potential for outperformance in the market [9].

FTAI Aviation (FTAI) came out with quarterly earnings of $0.87 per share, missing the Zacks Consensus Estimate of $0.94 per share. This compares to earnings of $0.31 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -7.45%. A quarter ago, it was expected that this transportation infrastructure company would post earnings of $0.83 per share when it actually produced earnings of $0.84, delivering a surprise of 1.20%.Over the last ...

Group 1: Earnings Performance - TPG RE Finance Trust reported quarterly earnings of $0.24 per share, missing the Zacks Consensus Estimate of $0.26 per share, and down from $0.30 per share a year ago, representing an earnings surprise of -7.69% [1] - The company posted revenues of $37.03 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 0.56%, and down from $38.93 million year-over-year [2] - Over the last four quarters, TPG RE Finance Trust has not surpassed consensus EPS estimates and has topped consensus revenue estimates only once [2] Group 2: Stock Performance and Outlook - TPG RE Finance Trust shares have declined approximately 12.8% since the beginning of the year, compared to a -6% decline in the S&P 500 [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the coming quarter is $0.25 on revenues of $37.52 million, and for the current fiscal year, it is $1.03 on revenues of $149.72 million [7] Group 3: Industry Context - The Real Estate - Operations industry, to which TPG RE Finance Trust belongs, is currently ranked in the bottom 34% of over 250 Zacks industries, indicating potential challenges for stock performance [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact TPG RE Finance Trust's stock performance [5][6]